In episode 4, Murat talks with Andrew C. R. Martin, Professor of Bioinformatics and Computational Biology at UCL, about abYsis (a fully integrated antibody discovery system) and the latest antibody developability tools!

Following the origin story of abYsis, you will hear the differences between the public and commercial versions such as data persistence and security, as well as new tools such as abYmod and abYdraw.  

At the end of the talk, the discussion moves into developability (stability and Immunogenicity).

Antiverse - Engineering the future of drug discovery - https://www.antiverse.io/

To obtain an abYsis license contact Chemogenomix. 

To be an abYdraw beta tester contact Andrew Martin.